Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A PANEL DISCUSSION

The Summit theme "unlocking the $1 Trillion Wealth transfer in Dubai"

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 7, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it will present at the Family Office Summit in Dubai with the theme of "Unlocking the $1 Trillion Wealth Transfer in Dubai".

Panel Discussion Event Details

Date: October 9, 2025
Time: 11:20-11:50 a.m. local time
Location: Park Hyatt, Dubai

The summit will bring together thought leaders, opinion makers, executives and entrepreneurs from around the world to deliberate on unlocking the wealth transfer in Dubai.

Dr. Raza Bokhari, Medicus's Executive Chairman & CEO, in his presentation, will focus on innovation in biotech/life sciences sector, the role of Artificial intelligence (AI) in drug development as well as the United Arab Emirates (UAE) Genomic project as an untapped differentiator.

Additional information on the Family Office Summit is available on the event website at https://familyofficesummit.ae/dubai/.

Medicus is currently conducting a Phase 2 clinical study for SKNJCT-003 in nine (9) clinical sites across the United States which commenced randomizing patients in August 2024. SKNJCT-003 is a double blinded, placebo controlled triple arm proof of concept Phase 2 clinical study, designed to non-invasively treat basal cell carcinoma (BCC) of the skin using novel, patent protected, dissolvable Doxorubicin-containing microneedle arrays (D-MNA). In March 2025, the Company announced a positively trending interim analysis for SKNJCT-003 demonstrating more than 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed.In April 2025, the investigational review board approved to increase the number of participants in SKNJCT-003 to ninety (90) subjects. The Company is expanding its trial sites in Europe and has randomized more than 75% of the ninety (90) participants expected to be randomized in the study. In September 2025, the company received positive feedback from the Food and Drug Administration (FDA) regarding its Type C meeting supporting the development of Skinject, indicating that the company may follow 505(b)(2) regulatory pathway to non-invasively treat BCC using dissolvable D-MNA.